Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis

Diagnostic Microbiology and Infectious Disease

Volumn 24, Issue 3, 1996, Pages 155-160

  Cormican, Martin G ^a   Erwin, Meredith E ^a   Marshall, Steven A ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0030094227     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/0732-8893(96)00016-8     Document Type: Article

References (20)

1. Barrier SL, Hindler JA (1993) Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease. Ann Pharmacother 27:309-310.
2. Barry AL, Pfaller MA, Fuchs PC, Packer RR (1994) In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 38:2419-2425.
3. Cormican MG, Jones RN (1995) Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and ofloxacin. J Clin Microbiol 33:215-216.
4. Cunliffe NA, Emmanuel FXS, Thompson CJ (1995) Lower respiratory tract infection due to ciprofloxacin resistant Morexella catarrhalis. J Antimicrob Chemother 36:273-274.
5. Doern GV (1992) In vitro susceptibility testing of Haemophilus influenzae: Review of new National Committee for Clinical Laboratory Standards recommendations. J Clin Microbiol 30:3035-3038.
6. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JR, Tobia AJ, Rosenthal ME (1992) In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 36: 860-866.
7. Hayakawa I, Akarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M (1986) Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother 29:163-164.
8. Jones RN, Doern GV, Baker C, Gerlach H, Hindler J (1993) Haemophilus test medium (HTM) susceptibility methods: Results of evaluations of reproducibility, stability, and medium quality. Antimicrob Newsltr 9:1-8.
9. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, The Fluoroquinolone Resistance Surveillance Group (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbio Infect Dis 19:203-215.
10. Laue RR, Kohner PC, Cockerill III FR (1995) Comparison of in-house and commercially prepared Haemophilus test media for disk diffusion testing of ampicillin against Haemophilus species. J Clin Microbiol 33:2240-2243.
11. Mendelman PM, Wiley EA, Stull TL, Clausen C, Chaffin DO, Onay O (1990) Problems with current recommendations for susceptibility testing of Haemophilus influenzae. Antimicrob Agents Chemother 34:1480-1484.
12. National Committee for Clinical Laboratory Standards (1993a) Approved standard M2-A5. Performance standards for antimicrobic disk susceptibility tests. National Committee for Clinical Laboratory Standards, Villanova, PA.
13. National Committee for Clinical Laboratory Standards (1993b) Approved standard M7-A3. Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Villanova, PA.
14. National Committee for Clinical Laboratory Standards (1994a) Approved guideline M23-A. Development of in vitro susceptibility testing criteria and quality control parameters. National Committee for Clinical Laboratory Standards, Villanova, PA.
15. National Committee for Clinical Laboratory Standards (1994b) Information supplement M100-S5. National Committee for Clinical Laboratory Standards, Villanova, PA.
16. Neu HC, Chin NX (1989) In vitro activity of S-ofloxacin. Antimicrob Agents Chemother 33:1105-1107.
17. Rittenhouse SF, Miller LA, Kaplan RL, Mosely GH, Poupard JA (1995) A survey of beta-lactamase-producing Haemophilus influenzae, an evaluation of 5750 isolates. Diagn Microbiol Infect Dis 21:223-225.
18. Scriver SR, Walmsley SL, Kau CL, Hoban DJ, Bronton J, McGeer A, Moore TC, Witwicki E, Canadian Haemophilus Study Group (1994) Determination of antimicrobial susceptibility of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Antimicrob Agents Chemother 38:1678-1680.
19. Sutton LD, Jones RN (1995) Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates. J Clin Microbiol 33:146-148.
20. Une T, Fujimoto T, Sato K, Osada Y (1988) In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 32:1336-1340.